Novartis AG Research and Development Expenses 2010-2024 | NVS
Novartis AG annual/quarterly research and development expenses history and growth rate from 2010 to 2024. Research and development expenses can be defined as an expense arising from studies and product development processes.
- Novartis AG research and development expenses for the quarter ending September 30, 2024 were $2.392B, a 39.06% decline year-over-year.
- Novartis AG research and development expenses for the twelve months ending September 30, 2024 were $9.747B, a 8.19% decline year-over-year.
- Novartis AG annual research and development expenses for 2023 were $11.371B, a 23.98% increase from 2022.
- Novartis AG annual research and development expenses for 2022 were $9.172B, a 3.86% decline from 2021.
- Novartis AG annual research and development expenses for 2021 were $9.54B, a 6.24% increase from 2020.
Novartis AG Annual Research and Development Expenses
(Millions of US $) |
| 2023 |
$11,371 |
| 2022 |
$9,172 |
| 2021 |
$9,540 |
| 2020 |
$8,980 |
| 2019 |
$9,402 |
| 2018 |
$8,489 |
| 2017 |
$8,972 |
| 2016 |
$9,039 |
| 2015 |
$8,935 |
| 2014 |
$9,086 |
| 2013 |
$9,071 |
| 2012 |
$8,588 |
| 2011 |
$9,583 |
| 2010 |
$9,070 |
| 2009 |
$7,469 |
Novartis AG Quarterly Research and Development Expenses
(Millions of US $) |
| 2024-09-30 |
$2,392 |
| 2024-06-30 |
$2,367 |
| 2024-03-31 |
$2,421 |
| 2023-12-31 |
$2,567 |
| 2023-09-30 |
$3,925 |
| 2023-06-30 |
$2,304 |
| 2023-03-31 |
$2,575 |
| 2022-12-31 |
$1,812 |
| 2022-09-30 |
$2,542 |
| 2022-06-30 |
$2,498 |
| 2022-03-31 |
$2,320 |
| 2021-12-31 |
$2,409 |
| 2021-09-30 |
$2,380 |
| 2021-06-30 |
$2,400 |
| 2021-03-31 |
$2,351 |
| 2020-12-31 |
$2,333 |
| 2020-09-30 |
$2,146 |
| 2020-06-30 |
$2,441 |
| 2020-03-31 |
$2,060 |
| 2019-12-31 |
$2,853 |
| 2019-09-30 |
$2,199 |
| 2019-06-30 |
$2,051 |
| 2019-03-31 |
$2,299 |
| 2018-12-31 |
$2,234 |
| 2018-09-30 |
$2,147 |
| 2018-06-30 |
$2,276 |
| 2018-03-31 |
$2,120 |
| 2017-12-31 |
$2,502 |
| 2017-09-30 |
$2,239 |
| 2017-06-30 |
$2,062 |
| 2017-03-31 |
$2,169 |
| 2016-12-31 |
$2,584 |
| 2016-09-30 |
$2,224 |
| 2016-06-30 |
$2,190 |
| 2016-03-31 |
$2,041 |
| 2015-12-31 |
$2,472 |
| 2015-09-30 |
$2,190 |
| 2015-06-30 |
$2,206 |
| 2015-03-31 |
$2,067 |
| 2014-12-31 |
$2,537 |
| 2014-09-30 |
$2,161 |
| 2014-06-30 |
$2,178 |
| 2014-03-31 |
$2,210 |
| 2013-12-31 |
$2,311 |
| 2013-09-30 |
$2,216 |
| 2013-06-30 |
$2,247 |
| 2013-03-31 |
$2,297 |
| 2012-12-31 |
$1,877 |
| 2012-09-30 |
$2,191 |
| 2012-06-30 |
$2,285 |
| 2012-03-31 |
$2,235 |
| 2011-12-31 |
$2,523 |
| 2011-09-30 |
$2,475 |
| 2011-06-30 |
$2,397 |
| 2011-03-31 |
$2,188 |
| 2010-12-31 |
$2,592 |
| 2010-09-30 |
$2,548 |
| 2010-06-30 |
$1,893 |
| 2010-03-31 |
$2,037 |
| 2009-12-31 |
$2,148 |
| 2009-09-30 |
$1,825 |
| 2009-06-30 |
$1,802 |
| 2009-03-31 |
$1,694 |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Large Cap Pharmaceutical |
$211.084B |
$45.440B |
|
Novartis has one of the strongest and broadest portfolio of oncology drugs and generics. It continues to build depth in 5 core therapeutic areas Cardio-Renal, Immunology, Neuroscience, Oncology and Hematology, strength in technology platforms - Targeted Protein Degradation, Cell Therapy, Gene Therapy, Radioligand Therapy, and xRNA. Novartis efforts to strengthen its wide and deep oncology portfolio by developing breakthrough treatments. Cosentyx, Entresto, Kesimpta, Zolgensma, Kisqali and Leqvio. In March 2015, Novartis acquired certain oncology products and pipeline compounds from Glaxo. In exchange, it sold its non-influenza Vaccines business to Glaxo. Also, the company has spun off the Alcon business into a separate company. In January 2015, Novartis divested its Animal Health division to Lilly. In July 2015, the company divested its influenza vaccines business to CSL Limited. Novartis has also acquired The Medicines Company, adding Leqvio, to its portfolio. Novartis sold its investment in Roche.
|
